1
|
Łowicki D, Przybylski P. Tandem construction of biological relevant aliphatic 5-membered N-heterocycles. Eur J Med Chem 2022; 235:114303. [PMID: 35344904 DOI: 10.1016/j.ejmech.2022.114303] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 03/14/2022] [Accepted: 03/15/2022] [Indexed: 12/20/2022]
Abstract
Nature often uses cascade reactions in a highly stereocontrolled manner for assembly structurally diverse nitrogen-containing heterocyclic scaffolds, i.e. secondary metabolites, important for medicinal chemistry and pharmacy. Five-membered nitrogen-containing heterocycles as standalone rings, as well as spiro and polycyclic systems are pharmacophores of drugs approved in various therapies, i.a. antibacterial or antiviral, antifungal, anticancer, antidiabetic, as they target many key enzymes. Furthermore, a large number of pyrrolidine derivatives are currently considered as drug candidates. Cascade transformations, also known as domino or tandem reactions, offer straightforward methods to build N-heterocyclic libraries of the great structural variety desired for drawing SAR conclusions. The tandem transformations are often atom economic and time-saving because they are performed as the one-pot, so no need for purification after each 'virtual' step and the limited necessity of protective groups are characteristic for these processes. Thus, the same results as in classical multistep synthesis can be achieved at markedly lower costs and shorter time, which is in line with modern green chemistry rules. Great advantage of cascade reactions is often reflected in their high regio- and stereoselectivities, enabling the preparing of the heterocyclic compound better fitted to the expected target in cells. This review reveals the biological relevance of N-heterocyclic scaffolds based on saturated 5-membered rings since we showed a number of examples of approved drugs together with the recent biologically attractive leading structures of drug candidates. Next, novel cascade synthetic procedures, taking into account the structure of the reactants and reaction mechanisms, enabling to obtain biological-relevant heterocyclic frameworks with good yields and relatively high stereoselectivity, were reviewed and compared. The review covers the advances of designing biological active N-heterocycles mainly from 2018 to 2021, whereas the synthetic part is focused on the last 7 years.
Collapse
Affiliation(s)
- Daniel Łowicki
- Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614, Poznan, Poland
| | - Piotr Przybylski
- Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614, Poznan, Poland.
| |
Collapse
|
2
|
Shishido R, Uesugi M, Takahashi R, Mita T, Ishiyama T, Kubota K, Ito H. General Synthesis of Trialkyl- and Dialkylarylsilylboranes: Versatile Silicon Nucleophiles in Organic Synthesis. J Am Chem Soc 2020; 142:14125-14133. [PMID: 32697080 DOI: 10.1021/jacs.0c03011] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Compared to carbon-based nucleophiles, the number of silicon-based nucleophiles that is currently available remains limited, which significantly hampers the structural diversity of synthetically accessible silicon-based molecules. Given the high synthetic utility and ease of handling of carbon-based boron nucleophiles, silicon-based boron nucleophiles, i.e., silylboranes, have attracted considerable interest in recent years as nucleophilic silylation reagents that are activated by transition-metal catalysts or bases. However, the range of practically accessible silylboranes remains limited. In particular, the preparation of sterically hindered and functionalized silylboranes remains a significant challenge. Here, we report the use of rhodium and platinum catalysts for the direct borylation of hydrosilanes with bis(pinacolato)diboron, which allows the synthesis of new trialkylsilylboranes that bear bulky alkyl groups and functional groups as well as new dialkylarylsilylboranes that are difficult to synthesize via conventional methods using alkali metals. We further demonstrate that these compounds can be used as silicon nucleophiles in organic transformations, which significantly expands the scope of synthetically accessible organosilicon compounds compared to previously reported methods. Thus, the present study can be expected to inspire the development of efficient methods for novel silicon-containing bioactive molecules and organic materials with desirable properties. We also report the first 11B{1H} and 29Si{1H} NMR spectroscopic evidence for the formation of i-Pr3SiLi generated by the reaction of i-Pr3Si-B(pin) with MeLi.
Collapse
Affiliation(s)
- Ryosuke Shishido
- Division of Applied Chemistry, Graduate School of Engineering, Hokkaido University, Sapporo, Hokkaido 060-8628, Japan
| | - Minami Uesugi
- Division of Applied Chemistry, Graduate School of Engineering, Hokkaido University, Sapporo, Hokkaido 060-8628, Japan
| | - Rikuro Takahashi
- Division of Applied Chemistry, Graduate School of Engineering, Hokkaido University, Sapporo, Hokkaido 060-8628, Japan
| | - Tsuyoshi Mita
- Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Hokkaido 001-0021, Japan
| | - Tatsuo Ishiyama
- Division of Applied Chemistry, Graduate School of Engineering, Hokkaido University, Sapporo, Hokkaido 060-8628, Japan
| | - Koji Kubota
- Division of Applied Chemistry, Graduate School of Engineering, Hokkaido University, Sapporo, Hokkaido 060-8628, Japan.,Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Hokkaido 001-0021, Japan
| | - Hajime Ito
- Division of Applied Chemistry, Graduate School of Engineering, Hokkaido University, Sapporo, Hokkaido 060-8628, Japan.,Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Hokkaido 001-0021, Japan
| |
Collapse
|
3
|
Liu B, Gai K, Qin H, Wang J, Liu X, Cao Y, Lu Q, Lu D, Chen D, Shen H, Song W, Mei J, Wang X, Xu H, Zhang Y. Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor. J Med Chem 2020; 63:5312-5323. [PMID: 32293179 DOI: 10.1021/acs.jmedchem.0c00082] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
We describe a study leading to the discovery of compound 11, a pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with excellent potency, metabolic stability, and pharmacokinetics (PK). Compound 11 incorporating a 4-silapiperidine group was discovered by further optimizing our previous lead with a triethylsilyl moiety. It displayed great potency against genotype 1 subtype a (GT1a), -1b, -2a, -3a, -4a, -5a, and -6a with an EC50 range of 0.33-17 pM and improved potency against the resistance-associated variant GT1a_M28T. Pharmacokinetics (PK) study indicated that compound 11 has reasonable PK exposures with a high liver distribution in preclinical animal species (mouse, rat, and dog). The results of a 14 day repeat-dose toxicity study identified the safety of compound 11.
Collapse
Affiliation(s)
- Baomin Liu
- Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Kuo Gai
- Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Hui Qin
- Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Jie Wang
- Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Xushi Liu
- Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Yuan Cao
- Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Qin Lu
- Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Dandan Lu
- Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Deyang Chen
- Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Hengqiao Shen
- Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Wei Song
- Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Jia Mei
- Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Xiaojin Wang
- Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Hongjiang Xu
- Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| | - Yinsheng Zhang
- Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China
| |
Collapse
|
4
|
Discovery of 3-Amino-2-Hydroxypropoxyisoflavone Derivatives as Potential Anti-HCV Agents. Molecules 2018; 23:molecules23112863. [PMID: 30400244 PMCID: PMC6278568 DOI: 10.3390/molecules23112863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Revised: 10/31/2018] [Accepted: 10/31/2018] [Indexed: 12/04/2022] Open
Abstract
Synthesis and anti-hepatitis C virus (anti-HCV) effects of certain 3-amino-2-hydroxy-propoxy isoflavone derivatives, 6a–i, were described. The known 3-(3,4-dimethoxyphenyl)-7-(oxiran-2-ylmethoxy)-4H-chromen-4-one (5) was reacted with substituted amines to give the desired isoflavone derivatives, 6a–i. Among them, 7-{3-[(3,4-dimethoxy-phenethyl)amino]-2-hydroxypropoxy}-3-(3,4-dimethoxyphenyl)-4H-chromen-4-one (6b) was the most active, exhibiting approximately 2-fold higher anti-HCV effects than standard antiviral drug ribavirin (EC50 of 6.53 vs. 13.16 μM). In addition, compound 6b was less cytotoxic than ribavirin. The selectivity index (SI) of 6b is approximately 2.6-fold higher than ribavirin. The compounds 6e, 6h, and 6i were also found to possess higher anti-HCV effects than ribavirin. Compound 6b was found to inhibit the HCV RNA expression in Ava5 cells in a dose-dependent manner; furthermore, we found that the antiviral mechanism of compounds 6b, 6e, 6h, and 6i gave rise to induction of HO-1 expression. With the HO-1 promoter-based analysis, we found compounds 6b, 6e, 6h, and 6i induced HO-1 expression through increasing Nrf-2 binding activity. Taken together, compound 6b may serve as a potential lead compound for developing novel anti-HCV agents.
Collapse
|
5
|
You Y, Kim HS, Park JW, Keum G, Jang SK, Kim BM. Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies. RSC Adv 2018; 8:31803-31821. [PMID: 35548241 PMCID: PMC9085918 DOI: 10.1039/c8ra05471a] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Accepted: 08/28/2018] [Indexed: 12/25/2022] Open
Abstract
Extremely potent, new hepatitis C virus (HCV) nonstructural 5A (NS5A) featuring substituted biaryl sulfate core structures was designed and synthesized. Based on the previously reported novel HCV NS5A inhibitors featuring biaryl sulfate core structures which exhibit two-digit picomolar half-maximal effective concentration (EC50) values against HCV genotype 1b and 2a, the new inhibitors equipped with the sulfate core structures containing diversely substituted aryl groups were explored. In this study, highly efficient, chemoselective coupling reactions between an arylsulfonyl fluoride and an aryl silyl ether, known as the sulfur(vi) fluoride exchange (SuFEx) reaction, were utilized. Among the inhibitors prepared based on the SuFEx chemistry, compounds 14, 15 and 29 exhibited two-digit picomolar EC50 values against GT-1b and single digit or sub nanomolar activities against the HCV GT-2a strain. Nonsymmetrical inhibitors containing an imidazole and amide moieties on each side of the sulfate core structures were also synthesized. In addition, a biotinylated probe targeting NS5A protein was prepared for labeling using the same synthetic methodology.
Collapse
Affiliation(s)
- Youngsu You
- Department of Chemistry, College of Natural Sciences, Seoul National University Seoul 08826 South Korea
| | - Hee Sun Kim
- Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology Pohang 37673 South Korea
| | - Jung Woo Park
- Supercomputing Modeling & Simulation Center, Division of Data Analysis, Korea Institute of Science and Technology Information (KISTI) 245 Daehak-ro, Yuseong-gu Daejeon 34141 South Korea
| | - Gyochang Keum
- Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology (KIST) Hwarangno 14-gil 5, Seongbuk-gu Seoul 02455 South Korea
| | - Sung Key Jang
- Department of Life Sciences, Pohang University of Science and Technology Pohang 37673 South Korea
| | - B Moon Kim
- Department of Chemistry, College of Natural Sciences, Seoul National University Seoul 08826 South Korea
| |
Collapse
|